Study #2022-0136
Phase Ib trial of the KRAS G12C inhibitor Adagrasib (MRTX849) in combination with the PARP inhibitor Olaparib in patients with KRAS G12C mutated advanced solid tumors, with a focus on gynecological, breast, pancreatic and KEAP1 mutated non-small cell lung cancers.
MD Anderson Study Status
Not Accepting
Treatment Agent
Adagrasib, Olaparib
Description
Evaluate safety and tolerability, while establishing the recommended dose of the investigational drug combination of adagrasib and olaparib that can be given to participants with advanced solid tumor(s) with a KRAS G12C and/or KEAP1 mutation.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor, Non-small Cell Lung Cancers
Study phase:
Phase I
Physician name:
Timothy Yap
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.